Latest News

All
News
Press Release

Select Category

AllNewsPress Release

Sirius Therapeutics Announces Nearly $50 million Financing to Accelerate Clinical Development of siRNA Therapeutics for Cardiometabolic Diseases

San Diego and Shanghai, May 9th, 2025 – Sirius Therapeutics today announced that it has successfully completed nearly $50 million Series B2 financing to advance clinical development of the Company’s novel siRNA therapeutics for cardiometabolic disorders and...

Sirius Therapeutics announces U.S. FDA Clearance of IND to Begin Clinical Trial of Novel siRNA Therapy for Hyperlipoproteinemia(a)

April 9, 2025, San Diego and Shanghai – Sirius Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to begin clinical trial of SRSD216, a novel small interfering...

Sirius Therapeutics announces NMPA Approval to Begin Phase 1 Clinical Trial in China of NovelsiRNA Therapy for Hyperlipoproteinemia(a)

March 20, 2025, San Diego, CA and Shanghai – Sirius Therapeutics today announced that the National Medical Products Administration (NMPA) of China has approved the company’s Investigational New Drug (IND) application to begin the first-in-human Phase...

Sirius Therapeutics Announces EMA Submission to Initiate a Phase 2 Clinical Trial of SRSD107, a Long–Acting, Next-Generation Anticoagulant for Thromboembolic Disorders

March 12, 2025, San Diego, CA & Shanghai – Sirius Therapeutics today announces it has submitted a clinical trial application to the European Medicines Agency (EMA) to begin a Phase 2 clinical trial of SRSD107, a next generation, long-acting Factor XI...

Sirius Therapeutics Submits IND Application to NMPA for Another Novel siRNA Therapy

Dec. 31, 2024, San Diego, CA and Shanghai – Sirius Therapeutics today announces that its submission of Investigational New Drug (IND) application for SRSD216, a novel siRNA therapeutic for the management of Hyperlipoproteinemia(a), is accepted by National...

Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

December 10, 2024, San Diego, CA & Shanghai – Sirius Therapeutics today announced promising preliminary data from its Phase 1 first-in-human clinical trial of SRSD107, a next generation siRNA therapeutics under clinical development for the prevention...